Aflibercept Injection

A selection of global experts in ophthalmology

Sponsored by Bayer AG

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Now Playing:

Aflibercept in DME: The Importance of an Intensive Treatment Regimen

Randomized controlled trials of anti-VEGF agents have shown that excellent outcomes can be achieved in patients with diabetic macular edema (DME). Mr. Ian Pearce presents key evidence from clinical trials to demonstrate the importance of intensive anti-VEGF treatment in the first year. Following an intensive treatment regimen with aflibercept achieves favorable DRSS outcomes, which is discussed by Dr. David Wong.

*EYLEA licensed posology allows for a treat and extend regimen after the first twelve months of treatment.

These presentations contain information regarding indications and/or instructions which may differ from the approved use in your country. For complete information on products, please refer to the respective product monograph available through local regulatory authorities.

Statements of fact and opinions expressed are those of the speakers and do not necessarily reflect the opinions or position of the sponsor (Bayer)

Product Information »

G.MKT.SM.STH.06.2017.1355